Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
Zealand Pharma AS ZEAL
News
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)
Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)
Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma – Notification of holding of treasury shares
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
United States